Emergent BioSolutions Restructures

Emergent BioSolutions, with its second quarter financial results, announced a restructuring initiative expected to result in annualized savings of approximately $40 million when fully implemented.

Efforts aim to improve overall cost structure, drive efficiencies and align resourcing needs of the organization; and includes eliminating approximately 90 roles.

According to the company, creation of a new growth organization aims to integrate R&D capabilities, business development, strategy into one function led by Stephanie Duatschek, Senior Vice President, Chief Global Strategy & Franchise Development Officer, who will assume the role of Executive Vice President, Chief Growth Officer, with responsibility for the Company’s strategic growth.

Revenue was $234.3 million in the second quarter, up 66%. The company reported a loss of $180.2 million worsening 1,402% versus prior year, largely due to a $191.3 million non-cash impairment charge.

Naloxone sales were down 22% in the quarter. Anthrax MCM sales were $12.3 million up 6%. Smallpox MCM sales were $101.6 million, up 150%. Other products accounted for $54.1 million, up from $6.2 million in 2Q25,which the company attributes to higher USG and international BAT® sales due to timing.

Revenues from Services increased $2.0 million, or 45%, as compared with 2Q25. The increase was primarily attributable to production activity at the Company’s Winnipeg facility.